CS logo
small CS logo
Charles Retina Institute

Germantown, Tennessee, United States
Ophthalmologist in Germantown, Tennessee
1432 Kimbrough Rd, Germantown, TN 38138

About Charles Retina Institute


"Charles Retina Institute is one of the world’s foremost retinal clinics, specializing in vitreoretinal diseases and surgery. We specialize in the treatment of retinal detachment, proliferative vitreoretinopathy, macular holes, diabetic retinopathy, age-related macular degeneration, epimacular membranes, retinopathy of prematurity, as well as other macular and vitreous problems."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
17
Genentech, Inc.
7
Apellis Pharmaceuticals, Inc.
2
Gyroscope Therapeutics Limited
2
Kodiak Sciences Inc
2
Bayer
1
Greater Houston Retina Research
1
Neurotech Pharmaceuticals
1
REGENXBIO Inc.
1
Total Rows: 9

Clinical Trials at Charles Retina Institute


During the past decade, Charles Retina Institute conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 11 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 7 clinical trials were completed. i.e. 38.9% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years33332244339977220000110033222233Started TrialsCompleted Trails201520162017201820192020202120220510
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
2014-10-06
2018-01-23
Terminated
975
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
2015-03-30
2017-06-02
Completed
96
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
2015-08-11
2017-09-26
Completed
273
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
2015-09-28
2019-03-28
Completed
225
A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
2016-03-21
2016-04-05
Completed
35
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
2016-04-27
2017-12-14
Completed
229
Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
2016-07-21
2018-01-31
Terminated
994
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
2017-01-27
2018-03-29
Completed
76

Rows per page:

1–34 of 34

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Charles Retina Institute" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Genentech, Inc." with 7 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Gyroscope Therapeutics Limited" with 2 trials sponsored and "Kodiak Sciences Inc" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Charles Retina Institute" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Novartis Pharmaceuticals" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "Clinical Trials Resource Group, LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.
Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 17Hoffmann-La Roche: 17Genentech, Inc.: 7Genentech, Inc.: 7Apellis Pharmaceuticals, Inc.: 2Apellis Pharmaceuticals, Inc.: 2GyroscopeTherapeutics Limited: 2GyroscopeTherapeutics Limited: 2Kodiak Sciences Inc: 2Kodiak Sciences Inc: 2Bayer: 1Bayer: 1Greater Houston RetinaResearch: 1Greater Houston RetinaResearch: 1Neurotech Pharmaceuticals: 1Neurotech Pharmaceuticals: 1REGENXBIO Inc.: 1REGENXBIO Inc.: 1

Created with Highcharts 11.1.0Top CollaboratorsChugai Pharmaceutical: 2Chugai Pharmaceutical: 2Novartis Pharmaceuticals: 2Novartis Pharmaceuticals: 2Regeneron Pharmaceuticals: 2Regeneron Pharmaceuticals: 2Clinical Trials ResourceGroup, LLC: 1Clinical Trials ResourceGroup, LLC: 1

Clinical Trials Conditions at Charles Retina Institute


According to Clinical.Site data, the most researched conditions in "Charles Retina Institute" are "Diabetic Macular Edema" (6 trials), "Geographic Atrophy" (6 trials), "Macular Edema" (4 trials), "Diabetic Retinopathy" (3 trials) and "Macular Degeneration, Age-Related" (3 trials). Many other conditions were trialed in "Charles Retina Institute" in a lesser frequency.

Clinical Trials Intervention Types at Charles Retina Institute


Most popular intervention types in "Charles Retina Institute" are "Drug" (31 trials), "Other" (8 trials), "Procedure" (5 trials), "Combination Product" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.
The name of intervention was led by "Faricimab" (11 trials), "Sham Procedure" (10 trials), "Aflibercept" (5 trials), "Ranibizumab" (5 trials) and "Lampalizumab" (3 trials). Other intervention names were less common.

Clinical Trials Genders at Charles Retina Institute


The vast majority of trials in "Charles Retina Institute" are 34 trials for "All" genders.

Clinical Trials Status at Charles Retina Institute


Currently, there are NaN active trials in "Charles Retina Institute". undefined are not yet recruiting, 5 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Charles Retina Institute, undefined suspended trials, and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Charles Retina Institute, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 19Phase 3: 19Phase 2: 12Phase 2: 12Phase 4: 2Phase 4: 2

Created with Highcharts 11.1.0Trials StatusActive, not recruiting: 13Active, not recruiting: 13Completed: 12Completed: 12Recruiting: 5Recruiting: 5Terminated: 4Terminated: 4